Seer, Inc.

NasdaqGS SEER

Seer, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -693.16%

Seer, Inc. EBIT Margin is -693.16% for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.88% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Seer, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -699.29%, a -4.00% change year over year.
  • Seer, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -672.38%, a 60.83% change year over year.
  • Seer, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,716.38%, a 74.81% change year over year.
  • Seer, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -6,812.96%.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
NasdaqGS: SEER

Seer, Inc.

CEO Dr. Omid C. Farokhzad M.D., Ph.D.
IPO Date Dec. 4, 2020
Location United States
Headquarters 3800 Bridge Parkway
Employees 147
Sector Health Care
Industries
Description

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

GBIO

Generation Bio Co.

USD 0.88

-4.35%

NRIX

Nurix Therapeutics, Inc.

USD 18.60

-2.16%

STTK

Shattuck Labs, Inc.

USD 1.12

-5.88%

ORIC

ORIC Pharmaceuticals, Inc.

USD 9.91

15.23%

MNOV

MediciNova, Inc.

USD 1.91

-4.02%

PEPG

PepGen Inc.

USD 2.72

-2.86%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

PHVS

Pharvaris N.V.

USD 16.00

-2.50%

SANA

Sana Biotechnology, Inc.

USD 3.63

4.91%

KYMR

Kymera Therapeutics, Inc.

USD 40.12

7.79%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

FHTX

Foghorn Therapeutics Inc.

USD 4.24

-2.97%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

QSI

Quantum-Si incorporated

USD 2.03

5.18%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

NKTX

Nkarta, Inc.

USD 2.21

-4.33%

StockViz Staff

January 15, 2025

Any question? Send us an email